← Leaderboards
Thomas M Lietman
University Of California San Francisco
$24,360,475
Attributed
$33,830,064
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,830,064 · 13
By mechanism
U10$12,783,612 · 4
UG1$11,173,668 · 3
R01$5,973,488 · 3
K12$3,297,526 · 1
R21$378,750 · 1
K08$223,020 · 1
Top collaborators
- Catherine Elizabeth Oldenburg13 shared
- Travis Christian Porco10 shared
- Jennifer Rose-Nussbaumer8 shared
- Yvonne Ou6 shared
- Kieran O'Brien2 shared
Most similar at University Of California San Francisco
Same institution · by research overlap
- Julius Schachter$3,522,895
Others in their field
Top investigators on “Antibiotics”
- Laurence H Baker · University Of Michigan At Ann Arbor$52,071,546
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,812,829
- Taha E Taha · Johns Hopkins University$37,363,329
- Urs Ochsner · Crestone, Inc.$36,950,837
- Deborah T Hung · Massachusetts General Hospital$36,871,538
- Ryan Cirz · Revagenix, Inc.$35,410,554
Research focus
AntibioticsBlindnessProgramsInfectionRandomizedTrachomaAzithromycinAreaCountryCommunitiesPrevalenceTransmission ProcessFundingChildSurveysChlamydia InfectionsSuccessCollaborationsLeadHygieneWorld Health OrganizationCorneal UlcerChlamydia TrachomatisRandomized Trial
Grant awards (75)
Résistance Evaluée contre la Vie des Enfants au Niger-Implementation et Recherche (REVENIR). Community antimicrobial resistance after azithromycin distribution: selection, spillover, co-selection$777,408
R01 · FY2025 · AI
UCSF-Proctor Clinician Vision Scholars K12 Program$640,451
K12 · FY2025 · EY
Forecasting Trachoma Control$403,750
R01 · FY2025 · EY · contact PI
Forecasting Trachoma Control - Diversity Supplement$39,909
R01 · FY2025 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$837,133
UG1 · FY2024 · EY
Résistance Evaluée contre la Vie des Enfants au Niger-Implementation et Recherche (REVENIR). Community antimicrobial resistance after azithromycin distribution: selection, spillover, co-selection$790,839
R01 · FY2024 · AI
UCSF-Proctor Clinician Vision Scholars K12 Program$531,415
K12 · FY2024 · EY
Forecasting Trachoma Control$403,750
R01 · FY2024 · EY · contact PI
Forecasting Trachoma Control - Diversity Supplement$52,071
R01 · FY2024 · EY · contact PI
Forecasting Trachoma Control$7,602
R01 · FY2024 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$793,062
UG1 · FY2023 · EY
Steroids and Cross-linking for Ulcer Treatment (SCUT II)$745,915
UG1 · FY2023 · EY · contact PI
UCSF-Proctor Clinician Vision Scholars K12 Program$531,415
K12 · FY2023 · EY
Forecasting Trachoma Control$403,750
R01 · FY2023 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$26,005
UG1 · FY2023 · EY
Kebele Elimination of Trachoma for Ocular Health$842,897
UG1 · FY2022 · EY
Steroids and Cross-linking for Ulcer Treatment (SCUT II)$796,194
UG1 · FY2022 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$766,312
UG1 · FY2022 · EY
UCSF-Proctor Clinician Vision Scholars K12 Program$531,415
K12 · FY2022 · EY
Azithromycin Reduction to Reach Elimination of Trachoma$73,360
UG1 · FY2022 · EY
Steroids and Cross-linking for Ulcer Treatment (SCUT II)$863,694
UG1 · FY2021 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$766,312
UG1 · FY2021 · EY
Kebele Elimination of Trachoma for Ocular Health$626,247
UG1 · FY2021 · EY
UCSF-Proctor Clinician Vision Scholars K12 Program$531,415
K12 · FY2021 · EY
Steroids and Cross-linking for Ulcer Treatment (SCUT II)$64,849
UG1 · FY2021 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$50,816
UG1 · FY2021 · EY
Steroids and Cross-linking for Ulcer Treatment (SCUT II)$12,968
UG1 · FY2021 · EY · contact PI
Steroids and Cross-linking for Ulcer Treatment (SCUT II)$903,252
UG1 · FY2020 · EY · contact PI
Azithromycin Reduction to Reach Elimination of Trachoma$813,579
UG1 · FY2020 · EY
UCSF-Proctor Clinician Vision Scholars K12 Program$531,415
K12 · FY2020 · EY
Steroids and Cross-linking for Ulcer Treatment (SCUT II)$87,070
UG1 · FY2020 · EY · contact PI
Kebele Elimination of Trachoma for Ocular Health$605,504
UG1 · FY2019 · EY
Steroids and Cross-linking for Ulcer Treatment (SCUT II)$470,208
UG1 · FY2019 · EY · contact PI
Forecasting Trachoma Control$393,570
R01 · FY2019 · EY · contact PI
Digital Detection of Infectious Eye Epidemics$366,114
R01 · FY2019 · EY · contact PI
Kebele Elimination of Trachoma for Ocular Health$587,022
UG1 · FY2018 · EY
Forecasting Trachoma Control$396,495
R01 · FY2018 · EY · contact PI
Digital Detection of Infectious Eye Epidemics$369,178
R01 · FY2018 · EY · contact PI
Kebele Elimination of Trachoma for Ocular Health$441,269
UG1 · FY2017 · EY
Forecasting Trachoma Control$399,420
R01 · FY2017 · EY · contact PI
Digital Detection of Infectious Eye Epidemics$376,013
R01 · FY2017 · EY · contact PI
Village Integrated Eye Workers Trial$178,534
U10 · FY2017 · EY · contact PI
Village Integrated Eye Workers Trial$450,589
U10 · FY2016 · EY · contact PI
Forecasting Trachoma Control$399,420
R01 · FY2016 · EY · contact PI
Digital Detection of Infectious Eye Epidemics$394,199
R01 · FY2016 · EY · contact PI
Village Integrated Eye Workers Trial$507,248
U10 · FY2015 · EY · contact PI
Myocotic Ulcer Treatment Trial$602,668
U10 · FY2014 · EY · contact PI
Village Integrated Eye Workers Trial$593,474
U10 · FY2014 · EY · contact PI
Myocotic Ulcer Treatment Trial$618,920
U10 · FY2013 · EY · contact PI
Village Integrated Eye Workers Trial$606,912
U10 · FY2013 · EY · contact PI
TANA II$483,003
U10 · FY2013 · EY · contact PI
Myocotic Ulcer Treatment Trial$598,400
U10 · FY2012 · EY · contact PI
TANA II$474,936
U10 · FY2012 · EY · contact PI
TANA II$257,691
U10 · FY2012 · EY · contact PI
Myocotic Ulcer Treatment Trial$114,665
U10 · FY2012 · EY · contact PI
Myocotic Ulcer Treatment Trial$655,786
U10 · FY2011 · EY · contact PI
TANA II$519,937
U10 · FY2011 · EY · contact PI
Myocotic Ulcer Treatment Trial$544,463
U10 · FY2010 · EY · contact PI
TANA II$472,706
U10 · FY2010 · EY · contact PI
Myocotic Ulcer Treatment Trial$563,201
U10 · FY2009 · EY · contact PI
Eliminating trachoma with repeat mass drug treatment$200,000
U10 · FY2009 · EY · contact PI
The Steroids for Cornea Ulcers Trial$200,000
U10 · FY2009 · EY · contact PI
The Steroids for Cornea Ulcers Trial$584,286
U10 · FY2008 · EY · contact PI
Eliminating trachoma with repeat mass drug treatment$397,730
U10 · FY2008 · EY · contact PI
The Steroids for Cornea Ulcers Trial$579,707
U10 · FY2007 · EY · contact PI
Eliminating trachoma with repeat mass drug treatment$430,885
U10 · FY2007 · EY · contact PI
The Steroids for Cornea Ulcers Trial$493,263
U10 · FY2006 · EY · contact PI
Eliminating trachoma with repeat mass drug treatment$382,051
U10 · FY2006 · EY · contact PI
The Steroids for Cornea Ulcers Trial$520,555
U10 · FY2005 · EY
Eliminating trachoma with repeat mass drug treatment$374,552
U10 · FY2005 · EY
Eliminating trachoma with repeat mass drug treatment$377,450
U10 · FY2004 · EY
Predicting Resistance: Validating Mathematical Models$189,375
R21 · FY2004 · AI
Predicting Resistance: Validating Mathematical Models$189,375
R21 · FY2003 · AI
TRANSMISSION DYNAMICS OF TRACHOMA$111,510
K08 · FY2001 · AI
TRANSMISSION DYNAMICS OF TRACHOMA$111,510
K08 · FY2000 · AI